Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 11;39(30):3377–3390. doi: 10.1200/JCO.21.00086

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

FIG A5. — Survival in the ALK analysis cohort (n = 1,092 patients) according to known prognostic factors. (A) EFS and OS in the ALK analysis cohort population (n = 1,092 patients). Five-year EFS (blue line) 40% (95% CI, 37 to 43); 5-year OS (red line) 49% (95% CI, 46 to 53). (B) OS according to age. Five-year OS in patients < 1 year of age at diagnosis (red line) 50% (95% CI, 37 to 61); in patients 1-1.5 years of age at diagnosis (blue line) 58% (95% CI, 49 to 66); in patients 1.5-5 years of age at diagnosis (green line) 50% (95% CI, 46 to 53); and in patients > 5 years of age at diagnosis (purple line) 43% (95% CI, 35 to 50); P = NS (pseudo-value regression). (C) OS according to number of involved MCs. Five-year OS in patients with localized disease (red line) 67% (95% CI, 58 to 75), in patients with involvement of one MC (blue line) 65% (95% CI, 55 to 73), two MCs (green line) 52% (95% CI, 46 to 58), or over two MCs (purple line) 41% (95% CI, 36 to 46); P < .001. (D) OS according to stage. Five-year OS in patients with localized disease (red line) 67% (95% CI, 58 to 75), in patients with stage 4 disease (blue line) 47% (95% CI, 44 to 50), or stage 4s disease (green line) 54% (95% CI, 25 to 76); P < .001. (E) OS according to MYCN amplification in stage 4 disease. Five-year OS in patients with MNA (blue line) 46% (95% CI, 41 to 51), in patients without MNA (red line) 48% (95% CI, 44 to 53), NS (pseudo-value regression). (F) OS according to treatment period, before (< March 2010) or after (> March 2010) the definition of HDC by BUMEL and immunotherapy maintenance as standard treatment. A significant improvement survival because of BUMEL and GD2 standard therapy is observed. Five-year OS in patients having been treated before March 2010 (red line) 46% (95% CI, 41 to 51) versus after March 2010 (blue line) 51% (95% CI, 47 to 56); P = .039.^3-5 BUMEL, busulfan and melphalan; cHR, crude hazard ratio; EFS, event-free survival; HDC, high-dose chemotherapy; HR, hazard ratio; MC, metastatic compartment; MNA, MYCN-amplified; NS, not significant; OS, overall survival; ref, reference.